NASDAQ · RLMD
Relmada Therapeutics, Inc.
$3.44+$0.09 (+2.69%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
Loading market information…
NASDAQ · NTRB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nutriband Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nutriband Inc.’s next earnings report is currently expected on Dec 7, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nutriband Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $667.00K0.0% vs estimate |
| Q4 2024 | Apr 28, 2025 | -$0.50-316.67% vs estimate | $642.00K0.0% vs estimate |
|---|
| Q3 2024 | Dec 3, 2024 | -$0.120.0% vs estimate | $646.00K-9.01% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.44+$0.09 (+2.69%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
$2.68+$0.01 (+0.37%)
Adagene Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.74% below the high.
$1.76-$0.03 (-1.68%)
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 50.56% below the high.
$2.00+$0.04 (+2.04%)
Fortress Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
$1.94-$0.05 (-2.51%)
XBiotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.6% below the high.
$1.19-$0.01 (-0.42%)
Gain Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.58% below the high.
$1.17-$0.06 (-4.88%)
Lite Strategy, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.23% below the high.
$3.58-$0.23 (-6.04%)
Adicet Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.38% below the high.
